Nanostructured Lipid Carriers For Inhaled Combination Therapy: Anticancer Drug And Sirna Co-Delivery A Strategic Platform for Overcoming Multi-Drug Resistance in Pulmonary Malignancies

EVOLUTION OF LIPID-BASED NANOCARRIERS

Lipid-based nanocarriers have undergone three decades of continuous architectural refinement to improve drug loading, physical stability, and biological performance. The evolutionary transition from vesicular liposomes to solid lipid matrices, and ultimately to spatially disordered nanostructured lipid carriers, reflects major breakthroughs in colloid chemistry and materials science ^[2].

first-generation vesicular and solid systems

Liposomes—spherical lipid bilayers enclosing aqueous cores—were the first nanocarriers translated to clinical practice. While effective for hydrophilic drugs, liposomes suffer from poor stability during nebulization, susceptibility to lipid oxidation, rapid drug leakage, and low encapsulation efficiency for highly lipophilic molecules. To address these instability issues, Solid Lipid Nanoparticles (SLNs) were developed in the early 1990s by replacing the aqueous core with a room-temperature solid lipid matrix ^[3].

SLNs provided significant protection to sensitive drug molecules against chemical degradation and offered controlled release kinetics. However, as colloidal research progressed, fundamental structural limitations of SLNs emerged during shelf-life storage assessments.

limitations of slns and introduction of nlcs

Although SLNs provided improved physical protection against chemical degradation, their highly ordered, perfect crystalline lipid lattices lead to significant drug expulsion during storage. As the solid lipid cools and transforms into its thermodynamically stable βpolymorphic modification, the space available for drug incorporation shrinks dramatically. Nanostructured Lipid Carriers (NLCs) were specifically engineered to overcome this fundamental structural flaw by blending solid lipids with spatially incompatible liquid lipids (oils) ^[4].

The introduction of liquid lipids distorts the rigid crystalline arrangement, forming an amorphous or highly imperfect matrix structure. This increased spatial void volume allows higher drug payloads and suppresses premature expulsion during storage.

COMPARATIVE ANALYSIS OF NANOCARRIER SYSTEMS

Understanding the operational differences between SLNs and NLCs is essential for rational aerosol formulation design. Table 1 provides a side-by-side comparative analysis of key physicochemical and operational parameters governing these two carrier generations ^[5].

Table 1: Physicochemical and Operational Comparison of SLNs vs. NLCs

polymorphic transitions and matrix mechanics

The core advantage of NLCs lies in suppressing the formation of perfect lipid crystals. When solid lipids undergo crystallization, they transition from unstable α and β' forms to the tightly packed β modification. In SLNs, this transition leaves no room for guest drug molecules, forcing them out of the matrix. In NLCs, the liquid lipid molecules interrupt this regular lattice formation, creating structural imperfections, voids, and amorphous domains that stably entrap hydrophobic chemotherapeutic drugs even during long-term storage ^[6].

Furthermore, the mobility of drug molecules within the liquid lipid nanocompartments prevents crystallization of the drug itself, maintaining it in a molecularly dispersed or amorphous state that favors rapid dissolution and release upon therapeutic targeting.

STRUCTURAL TYPES OF NLCS

Depending on the composition of the lipid mixture and the production methodology, three distinct structural models of Nanostructured Lipid Carriers can be produced: Imperfect Matrix Type, Amorphous Type, and Multiple Lipid Matrix Type ^[7].

Type I: Highly Imperfect Matrix Model

Type I NLCs are produced by blending solid lipids with low concentrations of liquid lipids (typically 70:30 down to 99:1 ratio). The spatial incompatibility created by differences in fatty acid chain length, saturation levels, and geometric structure prevents tight crystallization. The matrix contains widespread lattice defects that accommodate high payloads of hydrophobic drug molecules ^[8].

Type Ii: Amorphous / Non-Crystalline Model

Type II NLCs are formulated using specific structure-modifying liquid lipids, such as hydroxyoctacosanyl hydroxystearate or isopropyl myristate, mixed with solid lipids. Upon cooling, the particle solidifies into a non-crystalline, amorphous state. The total absence of a crystalline lattice completely prevents crystallization-induced drug expulsion during storage.

Type Iii: Multiple Oil-In-Solid-Lipid-In-Water (O/W/O) Model

Type III NLCs represent a nano-compartmentalized structure produced when the concentration of liquid lipid exceeds the solubility limit within the solid lipid phase. Phase separation occurs during cooling, forming microscopic oil nanocompartments dispersed throughout the solid lipid shell. This model is exceptionally effective for drugs whose solubility is significantly higher in liquid oil than in solid lipid.

EXCIPIENT SELECTION AND MATRIX ENGINEERING

Selecting biocompatible, non-toxic, and non-immunogenic excipients is critical for pulmonary drug delivery. Inhaled formulations must conform to strict regulatory standards regarding lung tissue tolerance and clearance kinetics ^[9].

Solid Lipids

Solid lipids form the structural scaffold of the NLC matrix. Frequently utilized solid lipids include:

• Glyceryl Monostearate (GMS): A monoacylglycerol providing high biocompatibility and moderate melting point (~55 °C), enabling easy emulsification.
• Precirol ATO 5 (Glyceryl Palmitostearate): A mixture of mono-, di-, and triglycerides that forms broad lattice imperfections upon cooling.
•  enate): Long-chain fatty acid ester exhibiting high lipophilicity and sustained drug release profiles.
• Stearic Acid & Palmitic Acid: Naturally occurring saturated fatty acids with wellcharacterized lung metabolic pathways via endogenous lipid processing systems.

Liquid Lipids (Oils)

Liquid lipids disrupt crystal formation and enhance drug solubility. Preferred liquid lipids include:

• Miglyol 812: Medium-chain triglyceride (MCT) oil providing exceptional solvent capacity for lipophilic anticancer agents.
• Squalene: An endogenous unsaturated triterpene lipid that enhances membrane interaction and fluidizes the core.
• Oleic Acid: An unsaturated omega-9 fatty acid that aids in particle size reduction and improves core lipophilicity ^[10].

Surfactants And Stabilization Systems

Surfactants prevent colloidal aggregation during high-pressure homogenization and preserve particle size integrity during nebulization shear stress. Non-ionic surfactants such as Polysorbate 80 (Tween 80), Pluronic F-68 (Poloxamer 188), and Lecithin

(phosphatidylcholine) are preferred due to low airway mucosal toxicity.

DUAL PAYLOAD DESIGN: CORE ENTRAPMENT & SURFACE SHELL

To achieve simultaneous delivery of hydrophobic chemotherapeutics and polyanionic nucleic acids, NLCs must be structurally engineered with two functionally distinct loading domains: a lipophilic inner core and a cationic outer surface]. shell ^[11

Core Entrapment Of Hydrophobic Chemotherapeutics

Small-molecule hydrophobic drugs (e.g., Paclitaxel, Doxorubicin, Cisplatin prodrugs) are dissolved directly in the molten lipid blend during thermal homogenization. As the system cools, the drug molecules remain trapped within liquid lipid droplets and crystalline matrix defect zones, achieving high encapsulation efficiencies (>90%) ^[12].

Cationic Surface Modification For Sirna Binding

Because small interfering RNA (siRNA) molecules are highly polyanionic and hydrophilic, they cannot be incorporated into the hydrophobic lipid core. To address this, cationic lipids such as DOTAP(1,2-dioleoyl-3-trimethylammoniumpropane), CTAB, or cationic polymers like Chitosan are incorporated into the lipid phase. This imparts a net positive surface charge (Zeta potential: +20 mV to +40 mV), driving rapid electrostatic complexation of the phosphate backbone of siRNA onto the particle exterior ^[13].

FORMULATION ENGINEERING & NANOMANUFACTURING

Scalable, reproducible nanomanufacturing processes are essential to transition NLC formulations from lab research to clinical practice. High-pressure homogenization (HPH) and microfluidic mixing represent the gold standards for industrial scale-up ^[14].

hot high-pressure homogenization (hot hph)

Hot HPH is the most widely adopted technique for lipid nanoparticle industrial scale-up. The process involves dissolving the drug in the molten lipid phase (5–10 °C above the solid lipid melting point), dispersing this phase in a hot aqueous surfactant solution using high-shear mixing, and passing the coarse emulsion through a high-pressure homogenizer (500–1500 bar) for several cycles ^[15]. quality by design (qbd) optimization

Applying Quality by Design (QbD) principles ensures robust formulation reproducibility. Critical Quality Attributes (CQAs)—including particle size (<200 nm), polydispersity index (PDI < 0.2), Zeta potential (>+25 mV), drug entrapment efficiency (>85%), and siRNA binding affinity—are mapped against Critical Process Parameters (CPPs) such as homogenization pressure, cycle number, and lipid-to-surfactant mass ratios using response surface methodologies ^[16].

PHYSICOCHEMICAL CHARACTERIZATION TECHNIQUES

Comprehensive characterization of dual-payload NLCs is required to ensure formulation quality, stability, and aerodynamic suitability prior to clinical inhalation testing.

Table 2: Key Physicochemical Characterization Parameters for Dual-Payload NLCs

Thermal And Crystallographic Characterization

Differential Scanning Calorimetry (DSC) measures changes in melting temperature (^T_m) and enthalpy (ΔH). Pure solid lipids exhibit sharp endothermic peaks reflecting high crystallinity. Upon incorporation of liquid lipids and drug molecules, the melting peak broadens and shifts to lower temperatures, while ΔH decreases significantly. This reduction in enthalpy confirms lattice disruption and the formation of the desired imperfect matrix ^[17].

AERODYNAMIC PERFORMANCE & DEPOSITION MECHANICS

The clinical efficacy of inhaled therapies depends entirely on site-specific aerosol deposition within the respiratory tract. Particles must navigate complex bronchial branching to reach peripheral tumor sites in the deep lung.

mass median aerodynamic diameter (mmad)

Aerosol deposition is governed by particle size, geometry, density, and airflow dynamics.

The key controlling metric is the Mass Median Aerodynamic Diameter (MMAD), defined as:

MMAD = d_g × √(ρ / ρ0)

where d_g is the geometric diameter, ρ is the particle envelope density, and ρ₀ is the reference density (1.0 g/cm³). For effective peripheral lung delivery, the MMAD must be strictly maintained between 1.0 μm and 5.0 μm ^[18].

Deposition Regimes

•  Inertial Impaction (>5.0 μm): Large aerosol droplets collide with the throat and upper airway bifurcations, leading to swallowing and systemic loss.
• Sedimentation (1.0–5.0 μm): Optimal size window where particles settle under gravity onto small airways and alveolar tumor tissues.
• Diffusion (<1.0 μm): Sub-micron particles remain suspended in the air stream and are largely exhaled before settling ^[19].

INHALATION DEVICES & AEROSOLIZATION DYNAMICS

Translating colloidal NLC suspensions into breathable aerosols requires selecting compatible inhalation devices that generate fine droplets without disrupting nanoparticle structure or damaging delicate siRNA payloads ^[20].

Vibrating mesh nebulizers vs. Legacy systems

Nebulizer selection directly impacts aerosol generation quality and payload integrity, as detailed in Table 3 ^[21].

Table 3: Comparison of Inhalation Devices for NLC Delivery

Dry Powder Inhalers (Dpi) & Spray Freeze-Drying

To improve long-term storage stability, liquid NLC dispersions can be converted into solid dry powders using spray-drying or spray freeze-drying. Sugars like trehalose, lactose, or mannitol act as lyoprotectants, replacing water molecules during drying to prevent nanoparticle aggregation and maintain dry powder dispersibility ^[22].

CELLULAR UPTAKE & INTRACELLULAR TRAFFICKING

Once deposited on the alveolar epithelium, NLCs must cross cellular membranes, avoid lysosomal degradation, and release both payloads into their respective intracellular target sites ^[23].

Endocytosis Pathways

The cationic surface charge of NLCs drives electrostatic interactions with negatively charged cell-surface proteoglycans, triggering rapid endocytosis via clathrin-mediated and caveolae-mediated pathways ^[24].

Endosomal Escape Via The Proton Sponge Mechanism

Following endocytosis, nanoparticles become trapped in early endosomes. Cationic lipids (e.g., DOTAP) and polymers (e.g., PEI, Chitosan) cushion endosomal acidification by absorbing protons pumped in by V-ATPase. This influx of protons drives counter-ion accumulation (Cl⁻), generating osmotic swelling, membrane rupture, and release of siRNA and chemotherapeutics into the cytosol ^[25].

OVERCOMING MULTI-DRUG RESISTANCE (MDR)

Multi-drug resistance (MDR) is a major obstacle in cancer chemotherapy, often caused by overexpressed membrane efflux pumps that rapidly pump cytotoxic drugs out of cancer cells ^[26].

Knockdown Of Efflux Transporters And Survival Genes

Combining chemotherapeutics with siRNA constructs targets the molecular drivers of therapeutic resistance ^[27].

• MDR1 / P-glycoprotein Knockdown: Target siRNA silences ABCB1 mRNA transcripts, inhibiting P-gp synthesis and blocking drug efflux.
• Bcl-2 Knockdown: Silencing anti-apoptotic Bcl-2 lowers the apoptotic threshold, making tumor cells susceptible to lower drug doses.
• Survivin Knockdown: Inhibiting Survivin restores caspase activity, promoting programmed cell death.

BIOLOGICAL BARRIERS & MUCUS PENETRATION STRATEGIES

Inhaled formulations must cross respiratory mucus layers and evade macrophage clearance before reaching underlying tumor cells.

Mucus Barrier Interactions

Airway mucus forms a dense viscoelastic hydrogel composed of crosslinked mucin glycoproteins. Unmodified cationic NLCs can become trapped in this layer via electrostatic interactions with negatively charged sialic acid and sulfonic residues on mucins, leading to rapid mucociliary clearance.

Pegylation And Mucus-Penetrating Coatings

Coating NLCs with low-molecular-weight Polyethylene Glycol (PEG, 2–5 kDa) creates a hydrophilic, charge-neutral surface layer. This steric barrier prevents mucin binding, allowing particles to diffuse rapidly through the mucus matrix toward the tumor surface ^[28].

PRECLINICAL IN VITRO EVALUATION MODELS

Evaluating inhaled nanomedicines requires in vitro models that closely mimic physiological pulmonary conditions and lung cancer microenvironments.

Air-Liquid Interface (Ali) Cell Culture Models

Traditional submerged cell cultures do not accurately reflect aerosol deposition or respiratory epithelial interactions. Air-Liquid Interface (ALI) cultures present bronchial epithelial cells (e.g., Calu-3, A549) grown on porous membranes, exposing the apical surface to air while the basolateral surface receives nutrients. This configuration allows realistic aerosol deposition testing using vibrating mesh nebulizers ^[29].

Table 4: Summary of In Vitro Evaluation Models for Pulmonary Delivery

3d Multicellular Tumor Spheroid Penetration

Multicellular tumor spheroids (MCTS) model the physical transport barriers seen in solid tumors. Confocal laser scanning microscopy (CLSM) tracking fluorescently labeled NLCs demonstrates deeper core penetration compared to free drug formulations, supporting their utility in treating dense tumor masses ^[30].

IN VIVO PHARMACOKINETICS & BIODISTRIBUTION

In vivo studies in orthotopic lung cancer models confirm the pharmacokinetic advantages of inhaled NLCs over intravenous systemic chemotherapy.

Lung Retention And Area Under Curve (Auc)

Inhaled NLC formulations achieve significantly higher lung tissue drug concentrations (AUClung) while drastically reducing peak plasma levels (Cmax, plasma). This targeted profile minimizes systemic exposure, protecting off-target organs such as the heart, kidneys, and liver from chemotherapy-induced toxicity.

Non-Invasive Whole-Body Optical Imaging

In vivo fluorescence molecular tomography (FMT) and PET tracking confirm that inhaled dual-payload NLCs remain localized in pulmonary tumor regions for up to 48 hours postinhalation, providing sustained therapeutic drug and siRNA levels throughout the treatment window ^[31].

SAFETY, PULMONARY TOXICITY & BIOCOMPATIBILITY

Evaluating the safety of inhaled nanomedicines requires thorough investigation of pulmonary inflammation, tissue biocompatibility, and systemic clearance pathways.

Bronchoalveolar Lavage Fluid (Balf) Analysis

In vivo safety studies assess acute lung inflammation by analyzing Bronchoalveolar Lavage Fluid (BALF) post-inhalation. Key biomarkers evaluated include:

• Pro-inflammatory Cytokines: Levels of TNF-α, IL-1β, and IL-6 remain within baseline physiological ranges for optimized NLC formulations.
• Total Protein and LDH Activity: Lactate dehydrogenase (LDH) activity and total protein concentration serve as indicators of cellular membrane damage and vascular leakage. Biocompatible lipid compositions produce no significant elevation in LDH activity.
• Cell Differential Counts: Neutrophil and macrophage counts remain normal, confirming the absence of acute immune activation ^[32].

Table 5: Safety and Biocompatibility Metrics in BALF Analysis